Eloralintide vs Retatrutide

    Eloralintide (LY3841136) and Retatrutide (LY3437943) are both investigational compounds, but they represent completely different bets on the next generation of obesity pharmacology. Retatrutide adds a third receptor (glucagon) to the incretin backbone; Eloralintide brings in the entirely separate amylin axis. This page compares them as research compounds.

    Development code
    LY3841136LY3437943
    Receptor targets
    Amylin receptors (selective)GLP-1, GIP, glucagon (triple)
    Mechanism family
    Amylin analogueIncretin + glucagon agonist
    Development stage
    ENLIGHTEN Phase 3TRIUMPH Phase 3
    Peak Phase 2 body-weight reduction
    9.5% to 20.1% at 48 weeks24.2% at 12mg by 48 weeks
    Phase 3 result
    Not yet reportedTRIUMPH-1: 17.6% to 25.0% at 80 weeks (placebo 3.9%)
    Typical combination partner
    Tirzepatide (dual incretin)Standalone triple agonist
    Peptx availability
    Factory Direct kits; UK single vials on waitlistUK single vials and Factory Direct kits

    Two very different approaches to next-gen obesity pharmacology

    Retatrutide's approach is receptor multi-agonism within a single molecule: keep the dual GLP-1/GIP incretin activity of Tirzepatide, then add a third arm at the glucagon receptor to drive additional adipose-mass change through hepatic pathways and thermogenesis. In Phase 2 it reached 24.2% at 48 weeks, and its Phase 3 TRIUMPH-1 trial reported up to 25.0% at 80 weeks.

    Eloralintide's approach is combination rather than multi-agonism: keep the incretin backbone as a separate molecule (Tirzepatide), and pair it with a selective amylin agonist that operates on an entirely different receptor family. The bet is that non-overlapping receptor pharmacology gives you flexibility, cleaner dose-titration, and potentially better tolerability than a single-molecule triple agonist.

    Which one is winning?

    It is too early to tell. Retatrutide is further along: its Phase 3 TRIUMPH-1 trial, published in September 2026, reported up to 25.0% at 80 weeks. Eloralintide reached 9.5% to 20.1% on its own in Phase 2, and combined with Tirzepatide it reached 23.3% in a 2026 Phase 2b in adults with type 2 diabetes. Eloralintide's Phase 3 has not reported, and no trial has compared the two directly.

    For research labs the two compounds are complementary. Retatrutide is the reference for studying receptor multi-agonism within a single molecule. Eloralintide is the reference for studying combination pharmacology across two mechanistically independent axes.

    Retatrutide and Eloralintide in one vial

    Retalora is a research blend of Retatrutide 10mg and Eloralintide 2.5mg in a single lyophilised vial, now in UK Express. See Retalora.

    Between them the two compounds act on four receptors: GLP-1, GIP, glucagon and amylin. Read what the research says about the two together and how this differs from a single-molecule quad agonist.

    Bottom line for research labs

    For research labs modelling next-generation obesity pharmacology, both compounds are relevant but they answer different questions. Retatrutide is the reference for triple-agonist single-molecule pharmacology and has the deepest monotherapy dataset. Eloralintide is the reference for selective amylin pharmacology and combination-with-incretin research. Serious mechanism-of-action work often uses both.

    Frequently asked questions

    Can Eloralintide and Retatrutide be combined?▼
    There is no published trial combining Eloralintide with Retatrutide; the closest published data pairs Eloralintide with Tirzepatide. For laboratory work, Peptx stocks Retalora in UK Express: Retatrutide 10mg and Eloralintide 2.5mg in one research vial.
    Is Retatrutide plus Eloralintide a quad agonist?▼
    Not strictly. A quad agonist is a single molecule acting on four receptors. Retatrutide acts on three (GLP-1, GIP and glucagon) and Eloralintide on a fourth (amylin), so together the two molecules cover four. The first single molecule on the same four receptors, CT-G32, reported its first animal data in November 2026.
    Which is easier to source as a research compound?▼
    Retatrutide has been in the research supply chain longer and is stocked at Peptx in 10mg through 60mg lyophilised vials. Eloralintide is newer. Eloralintide Factory Direct kits are available now. UK single vials are out of stock for now; join the waitlist on this page and we will email you when the next stock lands.
    Which is more potent for body-weight reduction research models?▼
    Retatrutide has the higher published figures as a single compound: 24.2% at 48 weeks in Phase 2 and up to 25.0% at 80 weeks in Phase 3 (12mg). Eloralintide's monotherapy Phase 2 reached 9.5% to 20.1% at 48 weeks; combined with Tirzepatide, a 2026 Phase 2b in type 2 diabetes reached 23.3%. The trials differ, so direct comparison depends on the research question.
    Is Eloralintide the same as Retatrutide?▼
    No. Eloralintide is a selective amylin receptor agonist. Retatrutide is a single molecule acting on GLP-1, GIP and glucagon receptors. Both are among the newest obesity research compounds, which is why they are often mentioned together.